newsfilter
← Latest News
Business Wire·

SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--SomaLogic, a global leader in proteomics technology, powered by a proprietary platform, the largest clinical proteomic database and next generation artificial intelligence and machine learning, and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction CM Life Sciences II will be renamed and its common stock will be listed on the Nasdaq Global Market under ticker symbol “SLGC.”